NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel's most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer. "We recently reported data from the ph ...

First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors from the enLIGHTEN™ Discovery PlatformDelivery of two unique payload combinations, predicted in silico using the enLIGHTEN™ Advanced Analytics suite, was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor therapy in preclinical models of cancerThis presentation accelerat ...

Candel Therapeutics, Inc.’s (CADL) shares skyrocketed 280.9% on Apr 5, after the company announced positive interim data from the phase II study evaluating its lead candidate, CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).The updated interim data from the ongoing phase II study showed that experimental treatment with CAN-2409 led to notable improvements in estimated median ove ...

Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer.CAN-2409 data sends Candel Therapeutics stock up Copy link to section Patients on CAN-2409 showed a meaningful increase in survival in a Phase II study, as per the biotechnology company. No new safety concerns were discovered in the clinical trial either. Garrett Nichols – the chief medical officer of $CADL said in a press release today:“CA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | --- | --- | |-----------------------------------------------------------------------------------------------------|------------------------------------------| | CANDEL (Exact name of Registrant as specified in its Charter) \nDelaware | THERAPEUTICS, INC. \n52-2214851 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 117 Kendrick St, Suite 450 Needham, MA (Address of principal ...

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights • Catalyst-rich 2024 paves way for transformational year Dr. Tak continued, "In 2024, we are expecting six data readouts across our three platforms, which include novel clinical and biomarker data in lung cancer, pancreatic cancer, and brain cancer, and a potentially registrational phase 3 clinical trial in prostate cancer. We look forward to sharing additional updates in the year ahead." o CAN-31 ...

NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, CA. The presentation will describe the second candidate from the enLIGHTEN™ Discover ...

NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate – for the treatment of patients with rec ...

Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase 3 clinical trial in prostate cancerFocusing on strategic key value drivers and catalysts, as a follow up to positive initial clinical and biomarker data in hard-to-treat cancersAdvancing the immunotherapy field with next-generation investigational therapies at the intersection of advanced analytics, biology and vectorologyExecuting on goal f ...

92 Condensed Consolidated Statements of Stockholders' Equity (In thousands, except share and per share amounts) (Unaudited) In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only ...